Biotechnology

BioScrip, Inc. announced 2010 second quarter revenue of $412.0 million, operating income of $13.5 million and net income of $3.1 million, or $0.06 per diluted share. Second quarter adjusted earnings per share was $0.07 per diluted share. Adjusted ...

Biocentric Energy Holdings, Inc. Dennis Fisher, Founder and Chairman of the Board today announced contracts for algae derived products are in the process of finalization:

As of July 30, 2010, the share capital in Diamyd Medical AB is 14,530,138.50 SEK. The total number of votes is 4,200,116 and the total number of shares is 29,060,277, divided among 1,437,876 shares of series A and 27,622,401 shares of series B .

Number of shares and votes in Active Biotech

Data on Basilea's Toctino(R) in daily medical practice in Germany presented at dermatology congress

Pacgen Biopharmaceuticals Corporation reported financial results from its fiscal year ended March 31, 2010 . Unless specified otherwise, amounts are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting ...

Pacgen Biopharmaceuticals Corporation reported financial results from its fiscal year ended March 31, 2010 . Unless specified otherwise, amounts are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting ...

Bradmer Completes Previously Announced Private Placement